Prospective study on the influence of radiochemotherapy on pituitary function in children with acute leukaemia and NHL.
To assess effects of chemo- and radiotherapy on the endocrine system 31 children with acute leukaemia and NHL (3 AML, 24 ALL, 4 NHL) were investigated. Children were treated according to modified BFM protocols. 25 patients were before, 5 during and one after puberty (2 to 16 y.). Before treatment, during induction therapy, during cranial irradiation, 4-6 weeks later and during maintenance therapy the following hormone values were estimated: TSH and prolactin basal and 30 min. after TRH (5 micrograms/kg i.v.), LH and FSH basal. Final investigations included total T4 and T3. In conclusion, chemo- und radiotherapy lead to transient elevations of TSH and prolactin in a few patients, but without proof for permanent disorders. Due to the fact all 3 patients with hyperprolactinaemia showed high prolactin levels (700 to 770 mU/l) already before treatment it is unlikely therapy was the main cause of these observed alterations. Although basal LH and FSH values were in normal ranges for age the increasing values after cranial irradiation in prepubertal children may reflect a possible initiation of early maturation, reported by others. Furthermore a retrospective growth study was performed in children treated with 2 different protocols. Protocol LSA2L2 used in the past before 1981 resulted in a permanent reduction of the height. In contrast, the mean SDS for height in children treated with protocol VII declined only during the intensive period of treatment. A catch-up growth occured already during maintenance therapy. Prophylactic cranial irradiation with 18 Gy in our patients under protocol LSA2L2 did not affect growth during the first 5 years after diagnosis.
Kluba
U
U
Department Pediatry, Central Laboratorium, Medival Academy, Magdeburg, GDR.
Mittler
U
U
Mohnike
K
K
Aumann
V
V
Kröning
G
G
Kapitza
W
W
Röppnack
R
R
D000208:Acute Disease; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000503:physiopathology / Q000532:radiotherapy; D008137:Longitudinal Studies; D007986:Luteinizing Hormone / Q000097:blood* / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000503:physiopathology / Q000532:radiotherapy; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011446:Prospective Studies; D013972:Thyrotropin / Q000097:blood* / Q000378:metabolism; D013973:Thyrotropin-Releasing Hormone
D013973:Thyrotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin